-
DE
Fostemsavir is an antiretroviral medication used to treat HIV-1 in heavily treatment-experienced adults when other therapies have failed.
Fostemsavir is an antiretroviral medication used to treat HIV-1 in heavily treatment-experienced adults when other therapies have failed.
Fostemsavir is an antiretroviral medication used in the treatment of HIV-1 infection. It belongs to the drug class known as attachment inhibitors and is marketed under the brand name Rukobia. The drug was specifically developed for heavily treatment-experienced adults who can no longer construct a viable antiretroviral regimen from other available drug classes due to resistance or tolerability issues.
Fostemsavir is a prodrug, meaning that after ingestion it is converted in the body into its active metabolite, temsavir. Temsavir binds directly to the gp120 glycoprotein on the surface of the HIV-1 virus. This prevents the virus from attaching to the CD4 receptor on human immune cells. Without this attachment, the virus is unable to enter the host cell and replicate. This unique mechanism of action distinguishes fostemsavir from all other antiretroviral drug classes, making it especially valuable for patients with multidrug-resistant HIV strains.
Fostemsavir must always be used in combination with other antiretroviral agents. It is not suitable as monotherapy. The standard dose is 600 mg twice daily, administered as extended-release tablets that can be taken with or without food. Treatment is initiated and monitored by a specialist in HIV medicine.
The drug is approved for heavily treatment-experienced adults living with HIV-1 infection who are unable to form a suppressive antiretroviral regimen from currently available drug classes due to resistance, contraindications, or intolerability.
Like all medicines, fostemsavir can cause side effects. The most commonly reported adverse effects include:
Serious side effects are rare but possible. Patients should contact their doctor promptly if they notice any unusual or unexpected symptoms.
Fostemsavir can interact with other medications. Of particular importance is the fact that strong CYP3A4 inducers (e.g. rifampicin, carbamazepine, St. John's wort) can significantly reduce plasma levels of fostemsavir, thereby reducing its effectiveness. Concurrent use of these substances is contraindicated. Interactions with certain other antiretroviral agents and statins (cholesterol-lowering drugs) must also be carefully considered.
Fostemsavir received approval in the European Union in 2020, based on the results of the BRIGHTE trial (Phase III study). This randomised, controlled study demonstrated that fostemsavir in combination with other antiretroviral agents produced a significant reduction in viral load and an increase in CD4 cell counts in heavily treatment-experienced patients, with a manageable safety profile.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.